CLINICAL TRIALS PROFILE FOR GB1211

Clinical Trials for GB1211

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03809052 ↗	A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects	Completed	Galecto Biotech AB	Phase 1	This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult subjects with indication of suspected Nonalcoholic steatohepatitis (NASH) and liver fibrosis.
NCT04607655 ↗	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis	Withdrawn	Covance	Phase 1/Phase 2	This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis
NCT04607655 ↗	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis	Withdrawn	Galecto Biotech AB	Phase 1/Phase 2	This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis
NCT05009680 ↗	A Single and Repeat Dose Trial in Participants With Hepatic Impairment	Recruiting	Comac Medical	Phase 1/Phase 2	This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh B and Child Pugh C)
NCT05009680 ↗	A Single and Repeat Dose Trial in Participants With Hepatic Impairment	Recruiting	Galecto Biotech AB	Phase 1/Phase 2	This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh B and Child Pugh C)
NCT05240131 ↗	A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).	Not yet recruiting	Hoffmann-La Roche	Phase 1/Phase 2	This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

Clinical Trial Conditions for GB1211

Condition Name

Condition Name
Intervention	Trials
Non-alcoholic Steatohepatitis (NASH)	1
Non-Small Cell Lung Cancer	1
Pharmacokinetics	1
Safety and Tolerability	1

Condition MeSH

Condition MeSH
Intervention	Trials
Liver Cirrhosis	2
Fibrosis	2
Non-alcoholic Fatty Liver Disease	2
Carcinoma	1

Clinical Trial Locations for GB1211

Trials by Country

Trials by Country
Location	Trials
Netherlands	1
Bulgaria	1
United Kingdom	1
United States	1

Trials by US State

Trials by US State
Location	Trials
Oregon	1

Clinical Trial Progress for GB1211

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	3
Phase 1	2

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	3
Not yet recruiting	1
Withdrawn	1

Clinical Trial Sponsors for GB1211

Sponsor Name

Sponsor Name
Sponsor	Trials
Galecto Biotech AB	6
Covance	1
Comac Medical	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	10
Other	4